#Scinai Immunotherapeutics #Israel #Yavne #Eilon Elmalem #Yavne Facility

Scinai Biopharma Services Appoints Eilon Elmalem as Site Head

In a strategic move to strengthen its operational leadership, Scinai Immunotherapeutics Ltd., listed on NASDAQ as SCNI, has announced the appointment of Eilon Elmalem as the new Site Head for its Yavne contract development and manufacturing organization (CDMO) facility. This significant transition will take effect on June 14, 2026, marking a pivotal moment in Scinai’s ongoing evolution within the biopharmaceutical landscape.

Elmalem's connection with Scinai is not new; he has spent the last two years as an external consultant, collaborating with the company on various CDMO activities and initiatives. His insights have proved invaluable during operational development processes, especially in the transition and integration planning for the Yavne facility. His new role will see him take full responsibility for site operations while continuing his involvement in engineering activities vital for the growth and stability of Scinai's CDMO platform.

With a formidable background spanning over 20 years in engineering, operations, and process development within the biotechnology and pharmaceutical industries, Elmalem is well-equipped for this leadership position. His previous experience includes senior roles at major corporations such as Merck and Sigma-Aldrich Millipore, where he notably served as the Vice President of Engineering and Process Development. His leadership throughout various multi-site operations in Israel, Europe, and the United States showcases his capability to manage complex organizational transformation projects and establish state-of-the-art GMP manufacturing facilities.

Leadership Insights

Amir Reichman, the Chief Executive Officer of Scinai, expressed his enthusiasm about Elmalem's appointment, stating, “We are thrilled to have Eilon stepping into this key leadership role. His deep knowledge and extensive operational experience will undoubtedly drive our CDMO platform's continued expansion and operational excellence. We are confident in his abilities to lead the Yavne facility toward greater success.”

The transition from the outgoing Site Head, Dr. Sylvia Kachalsky, who has played a crucial role in the Yavne facility for many years, is being meticulously managed to ensure continuity in operations. The knowledge transfer process began on May 10, 2026, with Dr. Kachalsky remaining involved throughout the integration phase, facilitating a smooth handover of responsibilities as she prepares to enter retirement later in the year.

Reichman also took the opportunity to acknowledge Dr. Kachalsky’s invaluable contributions over her tenure, saying, “Her leadership has significantly influenced the successful integration of the Yavne facility into Scinai Biopharma Services' expanding CDMO platform. We are grateful for her commitment and professionalism.”

Looking Ahead

With Elmalem at the helm, Scinai is poised to further its mission of advancing a robust pipeline of innovative immunology and inflammation therapies. The biopharmaceutical sector is constantly evolving, and Scinai’s commitment to enhancing its operational capabilities ensures that it remains competitive within this dynamic market.

As Scinai Immunotherapeutics continues to innovate, the strategic leadership of industry veterans like Elmalem will be crucial for the company’s sustained growth and success. As it charts the future of immunotherapy, all eyes will be on the advancements coming from the Yavne facility, a center poised for growth and excellence in biopharmaceutical development.